Literature DB >> 24639807

Pelvic abscess after oocyte retrieval in women with endometriosis: A case series.

Bárbara Romero, Laura Aibar1, Luis Martínez Navarro, Juan Fontes, Maria-Angeles Calderón, Juan Mozas.   

Abstract

BACKGROUND: Pelvic inflammatory disease with progression to pelvic abscess is a rare complication after oocyte retrieval during in vitro fertilization cycles. However, in patients with endometriosis the risk appears to be increased. Many authors agree on the need for antibiotic prophylaxis during the oocyte retrieval in these patients, but there is no consensus regarding the best antibiotic. CASE: We discuss 3 clinical cases of tubo-ovarian abscess in women with endometriosis after oocyte retrieval despite antibiotic prophylaxis between 2004 and 2011 at our center, and discuss our experience in the context of earlier reports.
CONCLUSION: It is unclear whether antibiotic prophylaxis is necessary in these women, and which antibiotic is best. Only douching with povidone-iodine appears to decrease the rate of pelvic infection.

Entities:  

Keywords:  Endometriosis; In vitro fertilization; Oocyte retrieval; Pelvic inflammatorydisease

Year:  2013        PMID: 24639807      PMCID: PMC3941372     

Source DB:  PubMed          Journal:  Iran J Reprod Med        ISSN: 1680-6433


Introduction

Endometriosis occurs in 25% to 50% of women with infertility (1, 2). In vitro fertilization is an effective treatment for these women, and although pelvic inflammatory disease (PID) is an infrequent complication of oocyte retrieval (OR) (0.3-0.4%), endometriosis is a risk factor to date only 9 cases of abscess after OR have been reported (3-15). We describe 3 cases of pelvic abscess after OR in women with endometriosis in southern Spain between 2004 and 2011.

Case series

Case 1 A 29 year old woman with a history of right ovarian cystectomy for endometriosis and severe adhesion syndrome was given 1500 mg cefuroxime intravenously during OR. Two bilateral endometriomas were seen and were not punctured. She became pregnant but later miscarried. During the second cycle cefuroxime was again used for prophylaxis during OR and the endometriomas were not punctured. She did not get pregnant. One month later she was hospitalized for an 8 cm pelvic abscess that required surgical drainage after her clinical status had improved with intravenous antibiotics. Case 2 A 32 year old woman with a 3 cm endometrioma diagnosed by ultrasound in her right ovary received vaginal douching during OR with povidone-iodine and saline solution. In addition, 1 g azithromycin was given orally and 1 g ceftriaxone was given intravenously in a single doses. Her endometrioma was punctured during OR. She did not get pregnant. Two months later she was hospitalized for a 9 cm pelvic abscess that did not resolve with intravenous antibiotics and required surgical drainage (Figure 1).
Figure 1

Pelvic abscess in a 32 years old women (Case 2).

Case 3 A 37 year old woman with a history of right ovarian cystectomy for endometriosis received vaginal douching during OR with povidone-iodine and saline solution; in addition, 1 g azithromycin was given orally. A 4 cm endometrioma was seen and was not punctured. She did not conceive. Three weeks later she was hospitalized for a 9 cm pelvic abscess (Figure 2), and responded favorably to intravenous antibiotic treatment. However, her abscess required surgical drainage and necessitated right adnexectomy.
Figure 2

Pelvic abscess in a 37 years old women (Case 3).

Pelvic abscess in a 32 years old women (Case 2). Pelvic abscess in a 37 years old women (Case 3).

Discussion

The frequency of PID after OR is difficult to establish since it is a rare complication. At our center, of 4319 OR procedures done between 2004 and 2011, there were only 3 cases of pelvic abscess (0.07%), all in women with endometriosis. One of the limitations that may contribute to this low complication rate is the lack of a pathological diagnosis of endometriosis, although the sensitivity and specificity of the diagnosis of endometrioma with ultrasonography were shown to be high (16). In two of our patients the diagnosis was confirmed pathologically, but in the third patient the diagnosis was based on ultrasound findings only. Moini et al identified 10 cases of PID among 5958 OR procedures, and 8 of these women had endometriosis (7). Chen et al analysed the association between endometriosis and pelvic abscesses in 3215 women and concluded that old blood in the endometrioma was an excellent culture medium; accordingly, they considered endometriosis to be an important risk factor for PID (10). Surgical treatment of endometriomas reduces the risk at the expense of diminishing follicular reserve, and thus prolonging stimulation cycles and increasing the cost of in vitro fertilization (17-20). Both the Royal College of Obstetricians and Gynecologists and the European Society of Human Reproduction and Embryology recommend resection for endometriomas measuring 4 cm or larger in order to reduce the risk of infection, among other aims (21, 22). Although there is no evidence of the efficacy of antibiotic prophylaxis during OR, most authors have used prophylaxis for women with endometriosis (23). Benaglia et al attempted to determine the frequency of pelvic abscesses in women after OR who were treated prophylactically with ceftriaxone 1 g intramuscularly for 4 days (24). Among 214 OR procedures, the involved ovary was not punctured in 12% of the cases, and in 3% the endometrioma was punctured accidentally. There were no cases of abscess. Egbase et al used ceftriaxone 2 g+ metronidazole 1 g intravenously, and among cultures of the embryo transfer catheter, 78% were negative, versus 30.9% in women who were not given prophylactic antibiotics (25). The conception rate was lower in women with a positive culture (18.7% vs. 41.3%). Weinreb et al treated oocyte donors prophylactically with cefoxitin 2 g or clindamycin 900 mg intravenously, and found that this reduced the risk of PID by 0.4% to 0% (26). However, the use of cefazolin for prophylaxis by Younis et al did not prevent the appearance of PID (9). To our knowledge only 9 cases of pelvic abscess after OR in women with endometriosis have been reported in 7 different studies (7, 9, 11-15). Eight of these women had received antibiotic prophylaxis, and in 6 of them the endometrioma had been punctured. These numbers suggest that antibiotic prophylaxis is not effective in preventing PID, although it would be interesting to know how many cases have been prevented by prophylaxis. Pelvic abscesses after OR may be underreported, as the present case series appears to suggest. At our centre all women with endometriosis who undergo in vitro fertilization are given antibiotics prophylactically during OR with azithromycin 1 g orally or ceftriaxone 1 g intramuscularly, or less frequently with cefuroxime 1500 mg or cefazolin 2 g intravenously. Yet despite antibiotic prophylaxis, 3 of the women at our centre developed pelvic abscesses (which required hospital treatment), and one woman, as in the study by Younis et al was resistant to antibiotic treatment (9). The endometrioma was punctured in only 1 of the 3 women described here, and 2 of them had a history of ovarian surgery- an antecedent that Chen et al identified as an additional risk factor (10). Tsai et al showed that vaginal douching with povidone-iodine before OR decreased the risk of o PID, although Van Os et al reported a lower conception rate in these women (8, 27). Hannoun et al have suggested the use of povidone-iodine followed by saline solution (28). Other preventive measures are the use of strict asepsis in the surgical field, avoiding successive punctures of the vaginal wall and ovarian capsule, and avoiding puncture and aspiration of the endometrioma during OR (23, 24).

Conclusion

Endometriomas 4 cm in diameter or larger should be respected. It is unclear whether antibiotic prophylaxis should be used during OR, or which agents are the most effective. Vaginal douching with povidone-iodine followed by saline solution appears to reduce the risk of PID.
  25 in total

1.  Pelvic abscess in the second half of pregnancy after oocyte retrieval for in-vitro fertilization: case report.

Authors:  J den Boon; C E Kimmel; H T Nagel; J van Roosmalen
Journal:  Hum Reprod       Date:  1999-09       Impact factor: 6.918

2.  Clinical complications during in-vitro fertilization treatment.

Authors:  T Bergh; O Lundkvist
Journal:  Hum Reprod       Date:  1992-05       Impact factor: 6.918

3.  Effect of betadine vaginal preparation during oocyte aspiration in in vitro fertilization cycles on pregnancy outcome.

Authors:  Antoine Hannoun; Johnny Awwad; Tony Zreik; Ghina Ghaziri; Antoine Abu-Musa
Journal:  Gynecol Obstet Invest       Date:  2008-09-18       Impact factor: 2.031

4.  Effects of previous ovarian surgery for endometriosis on the outcome of assisted reproduction treatment.

Authors:  Selmo Geber; Daniela Parreiras Ferreira; Luis Felipe Víctor Spyer Prates; Liana Sales; Marcos Sampaio
Journal:  Reprod Biomed Online       Date:  2002 Sep-Oct       Impact factor: 3.828

5.  Endometriosis may contribute to oocyte retrieval-induced pelvic inflammatory disease: report of eight cases.

Authors:  Ashraf Moini; Kiarash Riazi; Vida Amid; Mahnaz Ashrafi; Ensieh Tehraninejad; Tahereh Madani; Monir Owj
Journal:  J Assist Reprod Genet       Date:  2005-08       Impact factor: 3.412

6.  Outcome of in vitro fertilization/intracytoplasmic sperm injection after laparoscopic cystectomy for endometriomas.

Authors:  Ibrahim Esinler; Gurkan Bozdag; Funda Aybar; Ulku Bayar; Hakan Yarali
Journal:  Fertil Steril       Date:  2006-05-11       Impact factor: 7.329

7.  Prophylactic antibiotics and endocervical microbial inoculation of the endometrium at embryo transfer.

Authors:  P E Egbase; E E Udo; M Al-Sharhan; J G Grudzinskas
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

Review 8.  The effect of surgical treatment for endometrioma on in vitro fertilization outcomes: a systematic review and meta-analysis.

Authors:  Ioanna Tsoumpou; Maria Kyrgiou; Tarek A Gelbaya; Luciano G Nardo
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

9.  The efficiency of transvaginal ultrasonography in the diagnosis of endometrioma.

Authors:  V Mais; S Guerriero; S Ajossa; M Angiolucci; A M Paoletti; G B Melis
Journal:  Fertil Steril       Date:  1993-11       Impact factor: 7.329

Review 10.  A case of pregnancy complicated by the development of a tubo-ovarian abscess following in vitro fertilization and embryo transfer.

Authors:  Yuko Matsunaga; Kotaro Fukushima; Masahiro Nozaki; Naoyuki Nakanami; Yoshiaki Kawano; Toshiyuki Shigematsu; Shoji Satoh; Hitoo Nakano
Journal:  Am J Perinatol       Date:  2003-08       Impact factor: 1.862

View more
  5 in total

1.  Recommendations for good practice in ultrasound: oocyte pick up.

Authors:  Arianna D'Angelo; Costas Panayotidis; Nazar Amso; Roberto Marci; Roberto Matorras; Mircea Onofriescu; Ahmet Berkiz Turp; Frank Vandekerckhove; Zdravka Veleva; Nathalie Vermeulen; Veljko Vlaisavljevic
Journal:  Hum Reprod Open       Date:  2019-12-10

Review 2.  Assisted Reproductive Technology as a Transcutaneous Route for Bacterial Contamination of Ovarian Endometrioma with Coagulase-Negative Staphylococcus: Case Report and Review of the Literature.

Authors:  Shimon Edelstein; Inbar Ben Shachar; Hila Ben-Amram; Seema Biswas; Naama Marcus
Journal:  Infect Dis Obstet Gynecol       Date:  2019-11-29

3.  Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back.

Authors:  Sanjay K Agarwal; Warren G Foster
Journal:  Biomed Res Int       Date:  2015-07-12       Impact factor: 3.411

Review 4.  Antibiotic Prophylaxis for Gynecologic Procedures prior to and during the Utilization of Assisted Reproductive Technologies: A Systematic Review.

Authors:  Nigel Pereira; Anne P Hutchinson; Jovana P Lekovich; Elie Hobeika; Rony T Elias
Journal:  J Pathog       Date:  2016-03-07

5.  Middlemore Hospital experience with tubo-ovarian abscesses: an observational retrospective study.

Authors:  Antoine Youssef Habboub
Journal:  Int J Womens Health       Date:  2016-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.